Nanomedicine and Nanoscale Delivery (Focus Group - NND)
It has been shown that chemoresistance and immunosuppression in Pancreatic ductal adenocarcinoma (PDAC) can be overcome by inducing senescence to introduce therapeutic vulnerability [1]. We have shown Galectin-3 (Gal-3) overexpression in senescent PDAC cells, thus we developed Gal-3-targeting lipid nanoparticles (LNPs) encapsulating a BRD4-degrader for selective clearance. In murine PDAC models, we show that LNPs remodel the senescent tumor microenvironment (TME) resulting in improved survival. Here, we evaluate our LNP treatment on the senescent PDAC TME using 3D co-cultured “tumoroids.”
Leon J. M. W. Wagner, MSE
PhD Student
Weill Cornell Graduate School of Medical Sciences / Memorial Sloan Kettering Cancer Center
New York, New York, United States